Alisertib-Based Combo Improves Survival Outcomes in Ovarian, Breast Cancer
January 21, 2019 10:30 amBy Jessica Skarzynski
For some time now, paclitaxel has been considered standard of care in the treatment of patients with platinum-resistant ovarian cancer; however, recent research has shown the addition of the investigational drug alisertib to a paclitaxel regimen demonstrated … Read more